Subtopic Deep Dive
Sézary Syndrome Genomic Profiling
Research Guide
What is Sézary Syndrome Genomic Profiling?
Sézary Syndrome Genomic Profiling applies next-generation sequencing to identify somatic mutations, epigenetic changes, and driver alterations in this leukemic cutaneous T-cell lymphoma.
Studies using whole-exome and targeted sequencing reveal recurrent mutations in T-cell signaling genes like TNFR2, JAK-STAT pathway, and epigenetic modifiers (da Silva Almeida et al., 2015; 361 citations; Wang et al., 2015; 312 citations). Large cohorts highlight intratumor heterogeneity and branched evolution (Iyer et al., 2020; 60 citations). Over 10 key papers from 2009-2020 document ~2,000 citations total.
Why It Matters
Genomic profiling identifies actionable mutations like CTLA4-CD28 fusions enabling personalized therapies (Sekulić et al., 2014; 83 citations). KRAS/NRAS mutations suggest RAS/RAF/MEK inhibitor sensitivity in CTCL including Sézary (Kießling et al., 2011; 74 citations). These insights support precision medicine for aggressive disease, with TNFR2 alterations linked to immune evasion (Ungewickell et al., 2015; 269 citations) and Fas hypermethylation explaining apoptosis resistance (Jones et al., 2009; 64 citations).
Key Research Challenges
Intratumor Heterogeneity
Branched evolution creates diverse subclones within Sézary tumors, complicating targeted therapy (Iyer et al., 2020). Single biopsies miss variant allele frequencies across lesions. Multi-region sequencing is needed but resource-intensive.
Low Tumor Purity
Skin and blood samples in Sézary syndrome contain <20% malignant T-cells amid inflammatory infiltrates (da Silva Almeida et al., 2015). This reduces mutation detection sensitivity in NGS. Computational purification tools often fail in low-input samples.
Rare Driver Identification
Fusion genes like CTLA4-CD28 occur in <5% cases, requiring large cohorts for detection (Prasad et al., 2016; 88 citations). Epigenetic modifiers show variable methylation patterns (Kiel et al., 2015). Validating functional drivers demands orthogonal assays.
Essential Papers
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome
Ana Carolina da Silva Almeida, Francesco Abate, Hossein Khiabanian et al. · 2015 · Nature Genetics · 361 citations
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes
Linghua Wang, Xiao Ni, Kyle R. Covington et al. · 2015 · Nature Genetics · 312 citations
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
Alexander Ungewickell, Aparna Bhaduri, Eon J. Rios et al. · 2015 · Nature Genetics · 269 citations
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu et al. · 2019 · Journal of Clinical Oncology · 214 citations
PURPOSE To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS CITN-10 is a single-arm, multic...
Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome
Mark J. Kiel, Anagh A. Sahasrabuddhe, Delphine Rolland et al. · 2015 · Nature Communications · 194 citations
Abstract Sézary syndrome (SS) is an aggressive leukaemia of mature T cells with poor prognosis and limited options for targeted therapies. The comprehensive genetic alterations underlying the patho...
Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome
Aparna Prasad, Raquel Rabionet, Blanca Espinet et al. · 2016 · Journal of Investigative Dermatology · 88 citations
Personalized treatment of Sézary syndrome by targeting a novel <i><scp>CTLA</scp>4</i>:<i><scp>CD</scp>28</i> fusion
Aleksandar Sekulić, Winnie S. Liang, Waibhav Tembe et al. · 2014 · Molecular Genetics & Genomic Medicine · 83 citations
Abstract Matching molecularly targeted therapies with cancer subtype‐specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the ofte...
Reading Guide
Foundational Papers
Start with Sekulić et al. (2014; 83 citations) for CTLA4-CD28 fusion targeting proof-of-concept; Kießling et al. (2011; 74 citations) for RAS pathway mutations; Jones et al. (2009; 64 citations) for epigenetic Fas regulation.
Recent Advances
Iyer et al. (2020; 60 citations) on intratumor heterogeneity; Khodadoust et al. (2019; 214 citations) linking genomics to PD-1 therapy response; Prasad et al. (2016; 88 citations) on fusion genes.
Core Methods
Whole-exome sequencing (da Silva Almeida 2015); targeted capture (Ungewickell 2015); methylation arrays (Jones 2009); multi-region sampling for heterogeneity (Iyer 2020).
How PapersFlow Helps You Research Sézary Syndrome Genomic Profiling
Discover & Search
Research Agent uses citationGraph on da Silva Almeida et al. (2015) to map 361-cited works linking TNFR2/JAK-STAT mutations across 2015 Nature Genetics cluster. exaSearch queries 'Sézary syndrome whole-exome sequencing fusions' surfaces Prasad et al. (2016) and Sekulić et al. (2014). findSimilarPapers expands Wang et al. (2015) to 50+ CTCL genomic profiles.
Analyze & Verify
Analysis Agent runs readPaperContent on Kiel et al. (2015) to extract JAK-STAT mutation frequencies, then verifyResponse with CoVe cross-checks against Ungewickell et al. (2015) TNFR2 data. runPythonAnalysis processes variant allele frequencies from Iyer et al. (2020) using pandas for heterogeneity metrics; GRADE assigns A-grade evidence to recurrent drivers (da Silva Almeida et al., 2015).
Synthesize & Write
Synthesis Agent detects gaps in epigenetic modifier coverage beyond Kiel et al. (2015), flags contradictions between Fas methylation studies (Jones et al., 2009 vs. recent NGS). Writing Agent applies latexEditText to draft mutation tables, latexSyncCitations for 10-paper bibliography, latexCompile for review-ready manuscript, exportMermaid for signaling pathway diagrams.
Use Cases
"Extract mutation frequencies from Sézary genomic papers and plot variant burden distribution"
Research Agent → searchPapers('Sézary exome sequencing') → Analysis Agent → readPaperContent(da Silva Almeida 2015 + Wang 2015) → runPythonAnalysis(pandas groupby mutations, matplotlib violin plot) → CSV export of allele frequencies.
"Write LaTeX review section on TNFR2 mutations in Sézary syndrome"
Synthesis Agent → gap detection(TNFR2 therapeutic targets) → Writing Agent → latexEditText('TNFR2 recurrent in 25% SS; Ungewickell 2015') → latexSyncCitations(5 papers) → latexCompile → PDF with figure legends.
"Find code for CTCL mutation calling pipelines from papers"
Research Agent → paperExtractUrls(Kießling 2011) → Code Discovery → paperFindGithubRepo(RAS/RAF callers) → githubRepoInspect → runPythonAnalysis(test on Sekulić 2014 fusion data) → validated variant caller notebook.
Automated Workflows
Deep Research workflow scans 50+ CTCL papers via searchPapers, structures report with mutation prevalence tables from da Silva Almeida/Wang 2015 clusters, applies CoVe verification. DeepScan's 7-steps analyze Iyer et al. (2020) heterogeneity: readPaperContent → runPythonAnalysis(clonal evolution metrics) → GRADE evidence. Theorizer generates hypotheses linking TNFR2/JAK-STAT convergence to immune therapy resistance (Khodadoust et al., 2019).
Frequently Asked Questions
What is Sézary Syndrome Genomic Profiling?
Next-generation sequencing of tumor DNA/RNA from blood and skin identifies driver mutations in T-cell signaling (TNFR2, JAK-STAT) and epigenetic genes in this leukemic cutaneous lymphoma (da Silva Almeida et al., 2015).
What are main methods used?
Whole-exome sequencing detects somatic mutations (Wang et al., 2015); targeted panels identify fusions like CTLA4-CD28 (Sekulić et al., 2014); methylation arrays reveal Fas promoter hypermethylation (Jones et al., 2009).
What are key papers?
da Silva Almeida et al. (2015; 361 citations) maps mutational landscape; Wang et al. (2015; 312 citations) profiles signaling genes; Ungewickell et al. (2015; 269 citations) identifies TNFR2 alterations.
What open problems remain?
Intratumor heterogeneity hinders uniform targeting (Iyer et al., 2020); low tumor purity limits sensitivity; functional validation of rare fusions like CTLA4-CD28 needed beyond detection (Prasad et al., 2016).
Research Cutaneous lymphoproliferative disorders research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sézary Syndrome Genomic Profiling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers